Clinical Takeaway
In this rigorous crossover trial, neither a low nor a high single dose of CBD directly altered cortical excitability or produced measurable sedation in healthy adults. This suggests that CBD’s well-documented benefits in seizure disorders like Dravet syndrome and Lennox-Gastaut syndrome may depend largely on its interaction with co-administered medications such as clobazam rather than on a standalone brain-calming effect. Patients and clinicians should understand that CBD alone, at least as a single dose, may not be inherently anti-epileptic through direct neurological action.
#9 Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.
Citation: Gorbenko Andriy A et al.. Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.. Clinical pharmacology and therapeutics. 2026. PMID: 40836528.
Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0
This study clarifies that CBD’s clinical efficacy in seizure management may depend primarily on pharmacokinetic interactions with concurrent antiepileptic drugs rather than direct effects on cortical excitability, which has significant implications for how CBD is prescribed in polypharmacy regimens. Understanding that CBD lacks direct cortical suppression effects allows clinicians to better predict drug interactions and optimize combination therapy, particularly in patients taking clobazam or other hepatically metabolized anticonvulsants. These findings refine the mechanistic understanding necessary for appropriate clinical application of CBD and may explain variable treatment responses across different patient populations and medication combinations.
Abstract: Cannabidiol (CBD) is approved as an adjunctive treatment of seizures associated with Dravet syndrome, Lennox-Gastaut Syndrome, and tuberous sclerosis. Its therapeutic and adverse effects are thought to arise, at least partly, from a pharmacokinetic interaction with clobazam, another anti-seizure medication (ASM). The goal of this study was to evaluate the intrinsic anti-epileptic and sedative properties of CBD. A randomized, double-blind, placebo-controlled, 3-way crossover trial was conducted in 25 healthy males. On each visit, single doses of 30 mg CBD, 700 mg CBD, or placebo were administered orally. The effects of CBD on cortical excitability were measured using transcranial magnetic stimulation (TMS) combined with electromyography (EMG) and electroencephalography (EEG). Sedative properties were assessed using a validated CNS test battery. Pharmacokinetic sampling was performed. Data were analyzed using a mixed-effects model. CBD did not have significant effects on single pulse and paired pulse TMS-EMG parameters, compared to placebo. Some significant clusters were seen on paired pulse TMS-EEG at 3 hours post-dose for 30 mg CBD, and at 3 and 5 hours post-dose for 700 mg CBD. CBD did not have significant effects on any tests assessing its sedative properties. These results suggest that CBD may lack intrinsic anti-epileptic and sedative properties and that its effects could be primarily a product of interactions with other drugs, notably clobazam.
🧠 This well-designed crossover trial challenges a commonly held assumption about CBD’s mechanism in seizure management by demonstrating that CBD does not directly suppress cortical excitability in healthy volunteers, suggesting its clinical benefit in approved indications like Dravet syndrome may rely substantially on pharmacokinetic interactions with concurrent medications like clobazam rather than direct anti-seizure properties. The study’s use of healthy participants rather than patients with active seizure disorders is an important limitation, as altered brain physiology in epilepsy may unmask effects not apparent in baseline neural function. Additionally, the acute dosing paradigm may not capture effects that emerge with chronic administration or in the context of disrupted seizure thresholds. For clinicians prescribing CBD in combination therapy, this evidence reinforces the importance of monitoring drug interactions carefully and recognizing that efficacy in these patients likely depends on strategic polypharmacy rather than CBD acting as a standalone anti-convulsant. Future research should evaluate CBD’s effects in actual seizure populations and examine its syn